Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Journal of Diabetes and Metabolic Disorders
In the Phase 2 clinical trial (NEJM, 2023), retatrutide was administered subcutaneously at doses ranging from approximately 0.5 mg to 12 mg per week, with dose escalation under close medical supervision
Body measurements including waist, hips, thighs, and arms at consistent points provide direct feedback on composition changes
We do not encourage use of medications prescribed for human use in pets without first consulting with a primary care veterinarian
Each unit represents one injection administration event, a distinct drug administered by SC or IM route
Reconstitution of Retatrutide: Why This Should Only Occur in a Regulated Clinical Setting Retatrutide has no approved SmPC, so no authoritative reconstitution guidance exists
US$ 21.71
US$ 23.47
US$ 20.11
US$ 26.74
US$ 27.15
US$ 20.36
US$ 22.23
US$ 26.34
